Nivalis Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • 2ndary - Open

  • Investors
  • 1

Nivalis Therapeutics General Information

Description

Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.

Contact Information

Website
www.nivalis.com
Formerly Known As
N30 Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3122 Sterling Circle
  • Suite 200
  • Boulder, CO 80301
  • United States
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Alpine Immune Sciences
Vertical(s)
Life Sciences
Corporate Office
  • 3122 Sterling Circle
  • Suite 200
  • Boulder, CO 80301
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nivalis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Open Market 12-Apr-2018 Completed Generating Revenue
12. Merger/Acquisition 24-Jul-2017 Completed Profitable
11. Secondary Transaction - Open Market 22-Mar-2017 Completed Clinical Trials - Phase 1
10. IPO 17-Jun-2015 Completed Clinical Trials - Phase 1
9. Early Stage VC (Series 2) 24-Nov-2014 Completed Generating Revenue
8. Later Stage VC (Series E) 31-Jul-2012 Completed Pre-Clinical Trials
7. Later Stage VC (Series D) Completed
6. Debt - General 31-Dec-2011 Completed Generating Revenue
5. Debt - General 31-Mar-2011 $2.39M $59.5M Completed Generating Revenue
4. Later Stage VC (Series C2) $20M $57.1M Completed
To view Nivalis Therapeutics’s complete valuation and funding history, request access »

Nivalis Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series 2
Series 1
To view Nivalis Therapeutics’s complete cap table history, request access »

Nivalis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the
Biotechnology
Boulder, CO

Palo Alto, CA
 

Mont-Saint-Guibert, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nivalis Therapeutics Competitors (28)

One of Nivalis Therapeutics’s 28 competitors is BridgeBio Pharma, a Formerly VC-backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BridgeBio Pharma Formerly VC-backed Palo Alto, CA
Cellaïon Venture Capital-Backed Mont-Saint-Guibert, Belgium
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Corbus Pharmaceuticals Formerly VC-backed Norwood, MA
Metacrine Formerly VC-backed San Diego, CA
You’re viewing 5 of 28 competitors. Get the full list »

Nivalis Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bridger Management Hedge Fund Minority
Jennison Associates Hedge Fund Minority
RA Capital Management Venture Capital Minority
Rock Springs Capital Hedge Fund Minority
Sabby Management Hedge Fund Minority
You’re viewing 5 of 8 investors. Get the full list »

Nivalis Therapeutics Acquisitions (1)

Nivalis Therapeutics’s most recent deal was a Reverse Merger with Alpine Immune Sciences. The deal was made on 18-Apr-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alpine Immune Sciences 18-Apr-2017 Reverse Merger Pharmaceuticals
To view Nivalis Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Nivalis Therapeutics FAQs

  • When was Nivalis Therapeutics founded?

    Nivalis Therapeutics was founded in 2007.

  • Where is Nivalis Therapeutics headquartered?

    Nivalis Therapeutics is headquartered in Boulder, CO.

  • What industry is Nivalis Therapeutics in?

    Nivalis Therapeutics’s primary industry is Biotechnology.

  • Is Nivalis Therapeutics a private or public company?

    Nivalis Therapeutics is a Private company.

  • What is Nivalis Therapeutics’s current revenue?

    The current revenue for Nivalis Therapeutics is .

  • How much funding has Nivalis Therapeutics raised over time?

    Nivalis Therapeutics has raised $187M.

  • Who are Nivalis Therapeutics’s investors?

    Bridger Management, Jennison Associates, RA Capital Management, Rock Springs Capital, and Sabby Management are 5 of 8 investors who have invested in Nivalis Therapeutics.

  • Who are Nivalis Therapeutics’s competitors?

    BridgeBio Pharma, Cellaïon, Dicerna Pharmaceuticals, Corbus Pharmaceuticals, and Metacrine are some of the 28 competitors of Nivalis Therapeutics.

  • When was Nivalis Therapeutics acquired?

    Nivalis Therapeutics was acquired on 12-Apr-2018.

  • Who acquired Nivalis Therapeutics?

    Nivalis Therapeutics was acquired by Alpine Immune Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »